NO20020305L - Nye bisyklonukleosidanaloger - Google Patents

Nye bisyklonukleosidanaloger

Info

Publication number
NO20020305L
NO20020305L NO20020305A NO20020305A NO20020305L NO 20020305 L NO20020305 L NO 20020305L NO 20020305 A NO20020305 A NO 20020305A NO 20020305 A NO20020305 A NO 20020305A NO 20020305 L NO20020305 L NO 20020305L
Authority
NO
Norway
Prior art keywords
group
analogues
alpha
new
hydroxy
Prior art date
Application number
NO20020305A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020305D0 (no
Inventor
Takeshi Imanishi
Satoshi Obika
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20020305D0 publication Critical patent/NO20020305D0/no
Publication of NO20020305L publication Critical patent/NO20020305L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Saccharide Compounds (AREA)
  • Analogue/Digital Conversion (AREA)
  • Networks Using Active Elements (AREA)
  • Silicon Polymers (AREA)
NO20020305A 1999-07-22 2002-01-21 Nye bisyklonukleosidanaloger NO20020305L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20717099 1999-07-22
PCT/JP2000/004902 WO2001007455A1 (fr) 1999-07-22 2000-07-21 Analogues de bicyclonucléosides

Publications (2)

Publication Number Publication Date
NO20020305D0 NO20020305D0 (no) 2002-01-21
NO20020305L true NO20020305L (no) 2002-03-21

Family

ID=16535402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020305A NO20020305L (no) 1999-07-22 2002-01-21 Nye bisyklonukleosidanaloger

Country Status (24)

Country Link
US (2) US7217805B2 (xx)
EP (1) EP1201678B1 (xx)
JP (1) JP4151751B2 (xx)
KR (1) KR20020092894A (xx)
CN (1) CN1376161A (xx)
AT (1) ATE277066T1 (xx)
AU (1) AU766656B2 (xx)
BR (1) BR0012646A (xx)
CA (1) CA2380205C (xx)
CZ (1) CZ2002132A3 (xx)
DE (1) DE60014104T2 (xx)
DK (1) DK1201678T3 (xx)
ES (1) ES2226891T3 (xx)
HK (1) HK1044776A1 (xx)
HU (1) HUP0202812A3 (xx)
IL (1) IL147595A0 (xx)
MX (1) MXPA02000826A (xx)
NO (1) NO20020305L (xx)
NZ (1) NZ516653A (xx)
PL (1) PL352682A1 (xx)
PT (1) PT1201678E (xx)
RU (1) RU2227143C2 (xx)
WO (1) WO2001007455A1 (xx)
ZA (1) ZA200200398B (xx)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
JP4148662B2 (ja) * 2000-08-10 2008-09-10 第一三共株式会社 ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
JP2004508379A (ja) * 2000-09-07 2004-03-18 アベシア・バイオテクノロジー・インコーポレーテッド オリゴヌクレオチド合成用のシントン
KR20020069627A (ko) * 2001-02-27 2002-09-05 동부한농화학 주식회사 육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
EP2354148B1 (en) * 2002-02-13 2013-09-04 Takeshi Imanishi Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
ES2385828T3 (es) 2003-06-20 2012-08-01 Exiqon A/S Sondas, bibliotecas y kits para análisis de mezclas de ácidos nucleicos y procedimientos para construirlos
US8415100B2 (en) 2003-08-14 2013-04-09 Case Western Reserve University Methods and compositions for detecting gastrointestinal and other cancers
WO2005017207A2 (en) * 2003-08-14 2005-02-24 Case Western Reserve University Methods and compositions for detecting colon cancers
EP1688493B1 (en) * 2003-11-07 2008-08-13 Daiichi Sankyo Company, Limited Method of detecting genetic polymorphism
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US20070065840A1 (en) * 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
EP2505649A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCGR
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
CA2651453C (en) * 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
DK2092065T4 (da) 2006-10-18 2019-10-21 Ionis Pharmaceuticals Inc Antisense-forbindelser
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
US8084437B2 (en) * 2006-11-27 2011-12-27 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008074328A2 (en) * 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
EP2118118B1 (en) 2007-01-19 2017-09-27 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ES2376507T5 (es) * 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
WO2009067647A1 (en) * 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2229583B1 (en) 2007-12-06 2019-04-10 Genalyte Inc. Label-free nucleic acid synthesis monitoring system and method
WO2009100320A2 (en) * 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009124238A1 (en) * 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
DK2356129T3 (da) * 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US9846126B2 (en) 2008-10-27 2017-12-19 Genalyte, Inc. Biosensors based on optical probing and sensing
EP2421972A2 (en) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010150789A1 (ja) 2009-06-23 2010-12-29 武田薬品工業株式会社 核酸の合成法
WO2011010706A1 (ja) 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21シスエレメント結合物質
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US20110110860A1 (en) 2009-11-02 2011-05-12 The Board Of Regents Of The University Of Texas System Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
US9212390B2 (en) 2010-04-30 2015-12-15 Exiqon A/S In situ hybridization method and buffer
WO2011156278A1 (en) 2010-06-07 2011-12-15 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2012061778A2 (en) 2010-11-05 2012-05-10 Genalyte, Inc. Optical analyte detection systems and methods of use
EP3067421B1 (en) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
EP2495336B8 (en) 2011-03-04 2014-07-23 Roche Diagnostics GmbH A new type of universal probes for the detection of genomic variants
EP2742056B2 (en) 2011-08-11 2020-06-10 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2790736B1 (en) 2011-12-12 2018-01-31 Oncoimmunin, Inc. In vivo delivery of oligonucleotides
EP3907506A1 (en) 2012-03-12 2021-11-10 The Board of Trustees of the University of Illinois Optical analyte detection systems with magnetic enhancement and methods of their use
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2839006B1 (en) 2012-04-20 2018-01-03 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
ES2622716T3 (es) * 2012-09-21 2017-07-07 Osaka University Oligonucleótido y nucleósido artificial en puente con guanidina
ES2701235T3 (es) 2012-09-28 2019-02-21 Bna Inc Método de abrazadera de BNA
EP2906699A4 (en) 2012-10-11 2016-06-08 Ionis Pharmaceuticals Inc OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014093291A1 (en) 2012-12-10 2014-06-19 Advandx, Inc. Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest
JPWO2014112463A1 (ja) * 2013-01-15 2017-01-19 国立大学法人大阪大学 スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
US10086093B2 (en) 2013-02-28 2018-10-02 The General Hospital Corporation miRNA profiling compositions and methods of use
EP2961853B1 (en) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
EP2971142B1 (en) 2013-03-14 2020-06-24 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
RU2686080C2 (ru) 2013-05-01 2019-04-24 Ионис Фармасьютикалз, Инк. Композиции и способы
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
HUE050704T2 (hu) 2014-04-01 2020-12-28 Biogen Ma Inc Összetételek a SOD-1 expressziójának modulálására
EP3137476B1 (en) 2014-04-28 2019-10-09 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
RS59182B1 (sr) 2014-05-01 2019-10-31 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2963288A1 (en) 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
EP3234141A4 (en) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
AU2016295168B2 (en) 2015-07-17 2021-08-19 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
US10196639B2 (en) 2015-10-09 2019-02-05 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
EP3390636B1 (en) 2015-12-14 2021-05-19 Cold Spring Harbor Laboratory Antisense oligomers for treatment of dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
WO2017111137A1 (ja) * 2015-12-22 2017-06-29 味の素株式会社 オリゴヌクレオチドの製造方法
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
CA3013799A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN109952378B (zh) 2016-09-14 2024-09-17 詹森生物制药有限公司 经修饰的寡核苷酸及使用方法
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
WO2018102745A1 (en) 2016-12-02 2018-06-07 Cold Spring Harbor Laboratory Modulation of lnc05 expression
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
CA3071033A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019040923A1 (en) 2017-08-25 2019-02-28 Stoke Therapeutics, Inc. ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASE CONDITIONS AND OTHER DISEASES
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
JP2020533009A (ja) 2017-09-14 2020-11-19 ヤンセン バイオファーマ インク． ＧａｌＮＡｃ誘導体
EP3765476A2 (en) 2018-03-13 2021-01-20 Janssen Pharmaceutica NV Modified oligonucleotides for use in treatment of tauopathies
MX2020011695A (es) 2018-05-04 2021-02-26 Stoke Therapeutics Inc Métodos y composiciones para el tratamiento de la enfermedad por almacenamiento de éster de colesterilo.
JP7353301B2 (ja) 2018-05-07 2023-09-29 アルニラム ファーマスーティカルズ インコーポレイテッド 肝臓外送達
WO2020068398A2 (en) 2018-09-07 2020-04-02 The General Hospital Corporation Compositions and methods for immune checkpoint inhibition
TW202028465A (zh) 2018-09-28 2020-08-01 美商阿尼拉製藥公司 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關眼部疾病之使用方法
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
CN113646430A (zh) 2018-11-15 2021-11-12 Ionis制药公司 Irf5表达的调节剂
WO2020139871A1 (en) * 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
JP2022519532A (ja) 2019-01-31 2022-03-24 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｙａｐ１発現のモジュレーター
MX2021010152A (es) 2019-02-27 2021-09-14 Ionis Pharmaceuticals Inc Moduladores de la expresion de malat1.
MX2021013418A (es) 2019-05-03 2021-12-10 Dicerna Pharmaceuticals Inc Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas.
WO2020236600A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2021021673A1 (en) 2019-07-26 2021-02-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
CN114555621A (zh) 2019-08-15 2022-05-27 Ionis制药公司 键修饰的寡聚化合物及其用途
KR20220110749A (ko) 2019-11-06 2022-08-09 알닐람 파마슈티칼스 인코포레이티드 간외 전달
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
CN115843299A (zh) 2020-03-31 2023-03-24 詹森生物制药有限公司 寡核苷酸的合成和相关化合物
EP4150092A1 (en) 2020-05-11 2023-03-22 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
US20240336914A1 (en) 2020-12-31 2024-10-10 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
JP2024501857A (ja) 2020-12-31 2024-01-16 アルナイラム ファーマシューティカルズ， インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2022241408A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
JP2024519601A (ja) 2021-03-31 2024-05-20 エントラーダ セラピューティクス，インコーポレイティド 環状細胞透過性ペプチド
EP4337263A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
JP2024518476A (ja) 2021-05-10 2024-05-01 エントラーダ セラピューティクス，インコーポレイティド ｍＲＮＡスプライシングを調節するための組成物及び方法
WO2022271818A1 (en) 2021-06-23 2022-12-29 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
EP4367237A2 (en) 2021-07-09 2024-05-15 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
WO2023003922A1 (en) 2021-07-21 2023-01-26 Alnylam Pharmaceuticals, Inc. Metabolic disorder-associated target gene irna compositions and methods of use thereof
MX2024002640A (es) 2021-09-01 2024-07-19 Entrada Therapeutics Inc Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
CN118382708A (zh) 2021-12-10 2024-07-23 日东纺绩株式会社 用于检测核酸的对象碱基序列中的变异的方法、选择性地抑制核酸的扩增的方法、及用于实施这些的试剂盒
JP7394301B2 (ja) 2021-12-10 2023-12-08 日東紡績株式会社 二本鎖核酸の融解温度上昇化剤及びその用途
CN118369437A (zh) 2021-12-10 2024-07-19 日东纺绩株式会社 用于检测核酸的对象碱基序列中的变异的方法、选择性地抑制核酸的扩增的方法、及用于实施这些的试剂盒
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024040041A1 (en) 2022-08-15 2024-02-22 Dicerna Pharmaceuticals, Inc. Regulation of activity of rnai molecules
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
NZ209840A (en) 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4806463A (en) 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5591623A (en) 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
HUT69956A (en) 1990-08-14 1995-09-28 Isis Pharmaceuticals Inc Methode for inhibition of influenza virus by antiseuse oligonucleotides
US6111094A (en) 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
JP2708960B2 (ja) 1990-08-16 1998-02-04 アイシス・ファーマシューティカルス・インコーポレーテッド サイトメガウイルス感染の作用を変調するオリゴヌクレオチド
US5442049A (en) 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5691461A (en) 1990-08-16 1997-11-25 Isis Pharmaceuticals, Inc. Oligonucleotides inhibiting candida germ tube formation
US5242906A (en) 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
WO1994008003A1 (en) 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5582986A (en) 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
WO1992022651A1 (en) 1991-06-14 1992-12-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5607923A (en) 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5681747A (en) 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
AU699321B2 (en) 1995-04-07 1998-12-03 Mogens Havsteen Jacobsen Method of photochemical immobilization of ligands using quinones
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
ES2242291T5 (es) 1997-09-12 2016-03-11 Exiqon A/S Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US5955443A (en) 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem

Also Published As

Publication number Publication date
NO20020305D0 (no) 2002-01-21
IL147595A0 (en) 2002-08-14
US20040143114A1 (en) 2004-07-22
DE60014104D1 (de) 2004-10-28
CN1376161A (zh) 2002-10-23
RU2227143C2 (ru) 2004-04-20
ES2226891T3 (es) 2005-04-01
HK1044776A1 (en) 2002-11-01
US7217805B2 (en) 2007-05-15
US20070270370A1 (en) 2007-11-22
PL352682A1 (en) 2003-09-08
ATE277066T1 (de) 2004-10-15
DE60014104T2 (de) 2005-06-16
AU766656B2 (en) 2003-10-23
CA2380205A1 (en) 2001-02-01
HUP0202812A3 (en) 2005-01-28
JP2001089496A (ja) 2001-04-03
ZA200200398B (en) 2003-08-27
WO2001007455A1 (fr) 2001-02-01
CA2380205C (en) 2009-03-17
CZ2002132A3 (cs) 2002-05-15
PT1201678E (pt) 2004-11-30
EP1201678B1 (en) 2004-09-22
DK1201678T3 (da) 2004-10-18
JP4151751B2 (ja) 2008-09-17
US7994145B2 (en) 2011-08-09
AU6313500A (en) 2001-02-13
EP1201678A1 (en) 2002-05-02
HUP0202812A2 (hu) 2002-12-28
KR20020092894A (ko) 2002-12-12
NZ516653A (en) 2003-09-26
EP1201678A4 (en) 2002-10-02
BR0012646A (pt) 2002-04-09
MXPA02000826A (es) 2002-07-30

Similar Documents

Publication Publication Date Title
NO20020305L (no) Nye bisyklonukleosidanaloger
DK1152009T3 (da) Hidtil ukendte nucleosider og oligonucleotid-analoger
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
DE60127961D1 (de) Aminoalkoholderivate
HK1039316A1 (zh) 具有一氧化氮合成酶抑制作用的苯胺衍生物
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
DK0882728T3 (da) 1-methylcarbapenemderivater
GB0119863D0 (en) DNA-PK inhibitors
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application